Increased Cytokeratin 19 Fragment Levels Are Positively Correlated with Adenosine Deaminase Activity in Malignant Pleural Effusions from Adenocarcinomas

Table 2

Adenosine deaminase and cytokeratin 19 fragment levels in the pleural fluids of 119 patients with final diagnoses.

Diseases	Patients (n)	Adenosine deaminase, median (IU/L) (IQR)	Cytokeratin 19 fragments, median (ng/mL) (IQR)
Adenocarcinomas	30	9.41 (6.56–13.31)	98.96 (23.76–476.6)
Tuberculosis	28	39.08 (26.66–45.96)	16.72 (8.58–34.72)
Transudates	21	3.26 (2.09–7.73)	8.40 (5.91–13.94)
Parapneumonics	15	9.38 (5.68–9.97)	12.09 (6.06–28.86)
Empyemas	08	32.94 (16.07–61.70)	24.55 (2.03–205.3)
Squamous cell carcinomas	07	13.11 (11.08–18.65)	52.11 (24.63–236.2)
Lymphomas	04	21.64 (10.0–750.9)	14.99 (3.96–60.86)
Other	06	10.14 (5.26–24.30)	27.43 (14.61–32.40)

Abbreviations: IQR: interquartile range; ADA: adenosine deaminase; CK19: cytokeratin 19 fragments. Other diseases: Dressler syndrome (), melanocarcinoma (), chylothorax (), and leukemia (). Kruskal–Wallis test: for ADA () with for tuberculosis versus adenocarcinoma, parapneumonic, and transudate; for tuberculosis versus other groups. For CK19, () with for adenocarcinoma versus tuberculosis, transudate, and parapneumonic. Diseases remaining: .